2012年毕业于美国俄亥俄州立大学（The Ohio State University）药学院，获药剂学博士学位。2013年加入永利欢乐娱人城药理学与生物化学教研室，曾参与多项美国国家科学基金会（NSF）及美国国立卫生研究院（NIH）项目。目前主持国家自然科学基金（青年基金）1项，于2014年入选上海市科委浦江人才计划（A类），并获得2014年度“晨光学者”资助（A类），2019年上海市青年科技启明星（A类）。
主要研究方向为药物新剂型优化及其药理研究。
1. Y Mao*，J Wang, Y Zhao, Y Wu, KJ Kwak, C-S Chen, JC Byrd, RJ Lee, MA Phelps, LJ Lee & N Muthusamy. A Novel Liposomal Formulation of FTY720 (Fingolimod) for Promising Enhanced Targeted Delivery.Nanomedicine: NBM.,2014, 10, 393.
2. Y Mao*, G Triantafillou*, E Hertlein, W Towns, M Stefanovski, X Mo, D Jarjoura, M Phelps, G Marcucci, L J Lee, D Goldenberge, RJ. Lee, JC Byrd & N Muthusamy.Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-Cell Malignancies.Clin. Cancer Res., 2013, 19: 347.
3. B Yu*, Y Mao*, Y Yuan, C Yue, X Wang, X Mo, D Jarjoura, ME Parlaitis, RJ Lee, JC Byrd, LJ Lee & N Muthusamy. Targeted Drug Delivery and Cross-linking Induced Apoptosis with Anti-CD37 Based Dual-Ligand Immunoliposomes in B Chronic Lymphocytic Leukemia Cells. Biomaterials,2013, 34: 6185.
4. R Mani*, Y Mao*, FW Frissora, CL Chiang, J Wang, Y Zhao, Y Wu, B Yu, R Yan, X Mo, L Yu, J Flynn, J Jones, L Andritsos, S Baskar, C Rader, MA Phelps, CS Chen, RJ Lee, JC Byrd, LJ Lee & N Muthusamy. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia,2015,29(2): 346.
5. Y Mao*, J Wang*, Y Zhao, R Yan, H Li, CS Chen, RJ Lee, JC Byrd, LJ Lee, N Muthusamy& MA Phelps. Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.J Pharm Biomed Anal, 2014, 98:160
